RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in ...
RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals Kavigale ...
Pharmaceutical Technology12 天
Regdanvimab by Celltrion for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Regdanvimab is under clinical development by Celltrion and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
HMPV may be spreading in China. Here's what to know about this virus - and why it's not ...
Analysis - Five years on from the first news of Covid-19, recent reports of an obscure respiratory virus in China may ...
Taiwan News2 天
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against ...
Data showing continued in vitro neutralizing activity of PEMGARDA™ (pemivibart) against XEC have been submitted to the U.S. Food and Drug Administration (FDA), with a timely update to the PEMGARDA ...
'Quad-demic' overwhelms US hospitals as flu, Covid, RSV, and norovirus surge: Tips to stay safe
Hospitals in the USA are overwhelmed with a surge in patients due to a 'quad-demic' of flu, Covid-19, RSV, and norovirus.
Why The U.S. Could Be Making The Same Mistakes With Bird Flu As It Did With COVID-19
The first severe human case of bird flu was recently reported in the U.S. Here are some ways the U.S. may be repeating the ...
Pharmaceutical Technology13 天
Crizanlizumab by Novartis for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Coronavirus Disease 2019 (COVID-19).
infectiousdiseaseadvisor.com9 天
Paxlovid Reduces COVID-19-Related Hospitalization, Death Through Day 28
Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.